Current Cardiology Reports最新文献_第10页

Chronic Venous Insufficiency Evaluation and Medical Management. 慢性静脉功能不全评估和医疗管理。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-31 DOI: 10.1007/s11886-024-02119-1

Suman Wasan

引用次数: 0

Lymphatic System Development and Function. 淋巴系统的发育和功能

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-22 DOI: 10.1007/s11886-024-02120-8

Harish P Janardhan, Brianna T Wachter, Chinmay M Trivedi

{"title":"Lymphatic System Development and Function.","authors":"Harish P Janardhan, Brianna T Wachter, Chinmay M Trivedi","doi":"10.1007/s11886-024-02120-8","DOIUrl":"10.1007/s11886-024-02120-8","url":null,"abstract":"Purpose of review: This review delves into recent advancements in understanding generalized and organ-specific lymphatic development. It emphasizes the distinct characteristics and critical anomalies that can impair lymphatic function. By exploring developmental mechanisms, the review seeks to illuminate the profound impact of lymphatic malformations on overall health and disease progression.Recent findings: The introduction of genome sequencing, single-cell transcriptomic analysis, and advanced imaging technologies has significantly enhanced our ability to identify and characterize developmental defects within the lymphatic system. As a result, a wide range of lymphatic anomalies have been uncovered, spanning from congenital abnormalities present at birth to conditions that can become life-threatening in adulthood. Additionally, recent research highlights the heterogeneity of lymphatics, revealing organ-specific developmental pathways, unique molecular markers, and specialized physiological functions specific to each organ. A deeper understanding of the unique characteristics of lymphatic cell populations in an organ-specific context is essential for guiding future research into lymphatic disease processes. An integrated approach to translational research could revolutionize personalized medicine, where treatments are precisely tailored to individual lymphatic profiles, enhancing effectiveness and minimizing side effects.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":" ","pages":"1209-1219"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes. 肥胖作为 2 型糖尿病患者心脏病风险因素的作用。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-09-05 DOI: 10.1007/s11886-024-02129-z

Sushant Koirala, Michael Sunnaa, Thomas Bernier, Ahmet Afsin Oktay

{"title":"The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes.","authors":"Sushant Koirala, Michael Sunnaa, Thomas Bernier, Ahmet Afsin Oktay","doi":"10.1007/s11886-024-02129-z","DOIUrl":"10.1007/s11886-024-02129-z","url":null,"abstract":"Purpose of review: Cardiovascular disease (CVD) is the leading cause of death globally and is closely associated with obesity and type 2 diabetes mellitus (T2DM). This review examines the interplay between obesity, T2DM, and CVD, highlighting the increasing prevalence and economic burden of these conditions.Recent findings: Pharmacologic therapies, particularly glucagon-like peptide-1 receptor agonists, show promise in substantial weight loss and subsequent reduction of adverse cardiovascular events in obese individuals with and without diabetes. Obesity significantly contributes to the development of insulin resistance and T2DM, further escalating CVD risk. The common co-occurrence of these three conditions may involve several other pathophysiological mechanisms, such as chronic inflammation, increased visceral adiposity, and endothelial dysfunction. Until recently, lifestyle modifications and bariatric surgery had been the primary methods for weight loss and mitigating obesity-associated cardiovascular risk. Newer pharmacological options have led to a paradigm shift in our approach to obesity management as they provide substantial benefits in weight loss, glycemic control, and cardiovascular risk reduction.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":" ","pages":"1309-1320"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent Advances in Positron Emission Tomography Radiotracers to Image Cardiac Amyloidosis. 用于心脏淀粉样变性成像的正电子发射断层扫描放射性同位素的最新进展。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-13 DOI: 10.1007/s11886-024-02114-6

Ardel J Romero Pabón, Olivier F Clerc, Shilpa Vijayakumar, Sarah A M Cuddy, Sharmila Dorbala

引用次数: 0

Tackling the Disproportionate Burden of Resistant Hypertension in US Black Adults. 应对美国黑人成年人中不成比例的顽固性高血压负担。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-09-05 DOI: 10.1007/s11886-024-02115-5

Tina K Reddy, Samar A Nasser, Anuhya V Pulapaka, Constance M Gistand, Keith C Ferdinand

{"title":"Tackling the Disproportionate Burden of Resistant Hypertension in US Black Adults.","authors":"Tina K Reddy, Samar A Nasser, Anuhya V Pulapaka, Constance M Gistand, Keith C Ferdinand","doi":"10.1007/s11886-024-02115-5","DOIUrl":"10.1007/s11886-024-02115-5","url":null,"abstract":"Purpose of review: Elevated blood pressure is the leading modifiable risk factor for cardiovascular morbidity and mortality in the US. Older individuals, Black adults, and those with comorbidities such as chronic kidney disease, have higher levels of uncontrolled and resistant hypertension. This review focuses on resistant hypertension, specifically in the US Black population, including potential benefits and limitations of current and investigational agents to address the disparate toll.Recent findings: There is a necessity to implement public health measures, including early screening, detection, and evidence-based hypertension treatment with lifestyle, approved and investigational agents. The evidence highlights the importance of implementing feasible and cost-effective public health measures to advocate for early screening, detection, and appropriate treatment of hypertension. A team-based approach involving physicians, advanced practice nurses, physician assistants, pharmacists, social workers, and clinic staff to implement proven approaches and the delivery of care within trusted community settings may mitigate existing disparities.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":" ","pages":"1163-1171"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Healthy Lifestyle and Cardiac Rehabilitation for Weight Loss. 减肥的健康生活方式和心脏康复。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1007/s11886-024-02130-6

Christoph Höchsmann, James L Dorling, Carl J Lavie, Peter T Katzmarzyk

引用次数: 0

In Vivo and In Vitro Approaches to Modeling Hypoplastic Left Heart Syndrome. 左心发育不全综合征的体内和体外建模方法

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-09-28 DOI: 10.1007/s11886-024-02122-6

Matthew Alonzo, Javier Contreras, Jakob Bering, Ming-Tao Zhao

{"title":"In Vivo and In Vitro Approaches to Modeling Hypoplastic Left Heart Syndrome.","authors":"Matthew Alonzo, Javier Contreras, Jakob Bering, Ming-Tao Zhao","doi":"10.1007/s11886-024-02122-6","DOIUrl":"10.1007/s11886-024-02122-6","url":null,"abstract":"Purpose of review: Hypoplastic left heart syndrome (HLHS) is a critical congenital heart defect characterized by the underdevelopment of left-sided heart structures, leading to significant circulatory challenges, and necessitating multiple surgeries for survival. Despite advancements in surgical interventions, long-term outcomes often involve heart failure, highlighting the need for a deeper understanding of HLHS pathogenesis. Current in vivo and in vitro models aim to recapitulate HLHS anatomy and physiology, yet they face limitations in accuracy and complexity.Recent findings: In vivo models, including those in chick, lamb, and mouse, provide insights into hemodynamic and genetic factors influencing HLHS. In vitro models using human induced pluripotent stem cells offer valuable platforms for studying genetic mutations and cellular mechanisms. This review evaluates these models' utility and limitations, and proposes future directions for developing more sophisticated models to enhance our understanding and treatment of HLHS.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":" ","pages":"1221-1229"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Subcutaneous Furosemide in Heart Failure Management: A Systematic Review. 皮下注射呋塞米在心力衰竭治疗中的作用：系统回顾

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-10-01 DOI: 10.1007/s11886-024-02124-4

Wynne Widiarti, Pandit Bagus Tri Saputra, Melissa Valentina Ariyanto, Cornelia Ghea Savitri, Chaq El Chaq Zamzam Multazam, Johanes Nugroho Eko Putranto, Firas Farisi Alkaff

{"title":"The Role of Subcutaneous Furosemide in Heart Failure Management: A Systematic Review.","authors":"Wynne Widiarti, Pandit Bagus Tri Saputra, Melissa Valentina Ariyanto, Cornelia Ghea Savitri, Chaq El Chaq Zamzam Multazam, Johanes Nugroho Eko Putranto, Firas Farisi Alkaff","doi":"10.1007/s11886-024-02124-4","DOIUrl":"10.1007/s11886-024-02124-4","url":null,"abstract":"Background: Acute decompensated heart failure (ADHF) patients with symptomatic congestion often require in-hospital admission for intravenous (IV) diuretic, impacting both patient well-being and healthcare expenses. Subcutaneous (SC) furosemide has a potential to facilitate outpatient management of ADHF patients. Thus, this study aims to assess the efficacy and safety of SC furosemide utilization, offering a potential alternative to traditional IV administration.Methods: A systematic search was conducted until April 14 2024 across scientific databases. This review included studies comparing SC furosemide with oral and IV formulations in adult HF patients.Results: This study analyzed 687 patients from 20 studies. The results demonstrate that SC furosemide can effectively manage symptomatic congestion in HF patients and results in significant cost reductions, symptom relief, and improved quality of life. Although further investigation into mortality rates is needed, SC furosemide demonstrates efficacy comparable to IV furosemide in diuresis and weight loss, with similar bioavailability and natriuretic effects. Adverse events are generally minor, predominantly related to skin irritation. Innovative strategies, such as developing isotonic alkaline solutions and improved infusion devices, are being explored to address these challenges.Conclusion: SC furosemide offers a promising alternative for managing ADHF, particularly in symptomatic HF patients with volume overload. The integration of SC furosemide into routine clinical practice and future guidelines, could optimize the management of HF, reducing hospital admission and improving patient outcomes.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":" ","pages":"1285-1296"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute Pulmonary Embolism: Evidence, Innovation, and Horizons. 急性肺栓塞：证据、创新和前景。

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-31 DOI: 10.1007/s11886-024-02128-0

Stanislav Henkin, Francisco Ujueta, Alyssa Sato, Gregory Piazza

引用次数: 0

Impact of Visceral and Hepatic Fat on Cardiometabolic Health. 内脏和肝脏脂肪对心脏代谢健康的影响

IF 3.1 3区医学

Current Cardiology Reports Pub Date : 2024-11-01 Epub Date: 2024-09-05 DOI: 10.1007/s11886-024-02127-1

Tasveer Khawaja, Matthew Nied, Abigail Wilgor, Ian J Neeland

{"title":"Impact of Visceral and Hepatic Fat on Cardiometabolic Health.","authors":"Tasveer Khawaja, Matthew Nied, Abigail Wilgor, Ian J Neeland","doi":"10.1007/s11886-024-02127-1","DOIUrl":"10.1007/s11886-024-02127-1","url":null,"abstract":"Purpose of review: Body fat distribution plays a significant role in the cardiometabolic consequences of obesity. We review the impact of visceral and hepatic fat and highlight important interventions.Recent findings: Several epidemiologic studies have established a clear association between visceral fat and cardiovascular disease. The association between hepatic fat and cardiovascular disease is less clear with discordant results. Novel evidence demonstrates sodium glucose co-transporter-2 (SGLT2) inhibitors facilitate modest weight loss and reductions in ectopic fat depots in patient with type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists have been associated with decreased visceral/hepatic fat and reductions in MACE in populations with type 2 diabetes and with overweight/obesity. Clear associations between visceral fat and cardiometabolic outcomes have been established, whereas the impact of hepatic fat remains less clear. Lifestyle modification and pharmacologic interventions remain the initial therapies, while surgical intervention is associated with improved long-term outcomes. Emerging therapies have demonstrated a profound impact on body fat distribution and cardiometabolic risk.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":" ","pages":"1297-1307"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0